SynthesisFrontiers in pharmacology2025
A meta-analysis of the traditional herb Zicao and its active components for atopic dermatitis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The traditional Chinese herb Zicao and its bioactive constituents demonstrate therapeutic potential for atopic dermatitis (AD), and a systematic review assessing its effectiveness for managing AD is still lacking. Purpose: This meta-analysis aimed to synthesize the effects of Zicao on AD animal models and elucidate the underlying mechanisms. Methods: Ten databases (PubMed, Embase, Cochrane, Web of Science, China National Knowledge Internet (CNKI), VIP, CBM, Wanfang, Google Scholar, and ProQuest Dissertations & Theses Global) were systematically searched from the inception through May 2025. Study quality was assessed using SYRCLE's risk-of-bias tool. Random-effects models pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs) for primary outcomes (dermatitis severity and scratching behavior) and secondary outcomes (cytokines, epidermal thickness, and filaggrin (FLG)). Subgroup analyses examined the animal species, modeling method, drug formulation, and intervention protocol. Publication bias was evaluated via funnel plots and Egger's regression; sensitivity analyses utilized the leave-one-out methodology. Analyses were conducted in R version 4.3.2 software. Results: Ten studies (n = 316 animals) revealed the following: Zicao treatment significantly decreased the severity of dermatitis (SMD = -3.30, 95% CI: -4.37 to -2.23; Conclusion: The traditional Chinese herb Zicao ameliorates AD symptoms and Th2-associated inflammation but exhibits limited efficacy in epidermal barrier restoration. However, the pooled effect estimates from this meta-analysis must be interpreted with caution as the preliminary indications of potential efficacy rather than as conclusive evidence, given the widespread methodological limitations and the absence of pharmacokinetic and toxicological data in the included studies. Therefore, future investigations using chemically standardized preparations and comprehensive safety assessments are needed to validate these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023449172.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.